Anastasios Costarides, MD
Ophthalmology · Atlanta, GANPI 1689785230
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,500 of the $1,843 with a category attached, or 81.4%. Glaukos Corporation accounts for 82.1% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2020 at $1,620 and has fallen 93.6% since, to $104 in 2025. That places this record below the midpoint for ophthalmology clinicians in GA, where the typical reported total is $1,897.
Across 8 payments — averaging $230.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$2K
- AbbVie$331
Across 56 payments — averaging $2413.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$135K
What the payments were for
- Consulting fees$1,50081%
- Food & beverage$22312%
- Education$1207%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 2 | $1,512 |
| AbbVie(2 entities) | 6 | $331 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,843 in reported general payments places this provider in the 45th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 145 | $73,211 |
| LumiganBimatoprost | 130 | $69,818 |
| RestasisCyclosporine | 44 | $44,852 |
| CombiganBrimonidine Tartrate/Timolol | 57 | $24,699 |
| Latanoprost | 1,392 | $20,175 |
| Methazolamide | 73 | $19,647 |
| Prednisolone Acetate | 335 | $16,974 |
| Brimonidine Tartrate | 466 | $16,845 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 728 | $14,114 |
| AzoptBrinzolamide | 27 | $13,870 |
| Brinzolamide | 48 | $13,466 |
| VyzultaLatanoprostene Bunod | 26 | $12,561 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 48 | $11,546 |
| Travoprost | 66 | $10,762 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 56 | $10,463 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $331 | $139,368231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Atlanta
- Gagan SawhneyAtlanta$582K
- Lawrence WoodardAtlanta$578K
- Stephanie VanderveldtAtlanta$384K
- Steven YehAtlanta$289K
- Evan SchoenbergAtlanta$130K
- Robert StultingAtlanta$85K
- David SackelAtlanta$82K
- Atul SharmaAtlanta$77K
- Daniel MartinAtlanta$55K
- Douglas DayAtlanta$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.